{"entity":{"id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of ANS02 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.","summary":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07538804 by Avistone Biotechnology Co., Ltd., with 294 participants planned, started 2026-07-10 and due to reach its primary completion in 2029-06-30. Interventions recorded: ANS02.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07538804","url":"https://clinicaltrials.gov/study/NCT07538804"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07538804","phase":"1/2","setting":"A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Avistone Biotechnology Co., Ltd.","enrolled":294,"outcomes":[]},"route":"/trials/nct07538804/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}]}}